The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

BACKGROUND Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density. METHODS We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 microg subcutaneously daily; 27 men), or both (28 men). Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6. The bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured every six months with the use of dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured at base line and month 30 by means of quantitative computed tomography. Serum alkaline phosphatase levels were measured every six months. The primary end point was the rate of change in the bone mineral density at the posteroanterior spine. RESULTS The bone mineral density at the lumbar spine increased significantly more in men treated with parathyroid hormone alone than in those in the other groups (P<0.001 for both comparisons). The bone mineral density at the femoral neck increased significantly more in the parathyroid hormone group than in the alendronate group (P<0.001) or the combination-therapy group (P=0.01). The bone mineral density of the lumbar spine increased significantly more in the combination-therapy group than in the alendronate group (P<0.001). At 12 months, changes in the serum alkaline phosphatase level were significantly greater in the parathyroid hormone group than in the alendronate group or the combination-therapy group (P<0.001 for both comparisons). CONCLUSIONS Alendronate impairs the ability of parathyroid hormone to increase the bone mineral density at the lumbar spine and the femoral neck in men. This effect may be attributable to an attenuation of parathyroid hormone-induced stimulation of bone formation by alendronate.

[1]  S. Nussbaum,et al.  Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol , 2005, Osteoporosis International.

[2]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[3]  J. Hoover,et al.  New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. , 2003, Endocrinology.

[4]  A. Díez-Pérez,et al.  The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  P. Kulkarni,et al.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  H. Faber,et al.  Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[8]  R. Lindsay,et al.  Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. , 2000, The Journal of clinical endocrinology and metabolism.

[9]  E. Orwoll,et al.  Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.

[10]  C. Arnaud,et al.  Parathyroid hormone 1–34 (hpth 1–34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis — results from a placebo‐controlled randomized trial , 2000 .

[11]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Joseph Melton,et al.  Epidemiology of Fractures , 1999 .

[13]  J. Bilezikian,et al.  Osteoporosis in men : the effects of gender on skeletal health , 1999 .

[14]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[15]  T. Toth,et al.  Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. , 1998, JAMA.

[16]  R. Lindsay,et al.  Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  D. Bikle.  Biochemical markers in the assessment of bone disease. , 1997, The American journal of medicine.

[18]  R. Lindsay,et al.  Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis , 1997, The Lancet.

[19]  H. Harcke,et al.  Total Body Bone Mineral Density in Young Children: Influence of Head Bone Mineral Density , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  L. Stitt,et al.  A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[22]  John P. Bilezikian,et al.  Principles of Bone Biology , 1996 .

[23]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[24]  P. Delmas,et al.  The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? , 1995, Bone.

[25]  T. Wronski,et al.  Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. , 1995, Bone.

[26]  A. Klibanski,et al.  Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. , 1994, The New England journal of medicine.

[27]  T. Wronski,et al.  Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. , 1993, Endocrinology.

[28]  J. Hock,et al.  Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  D. Drost,et al.  Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. , 1991, Bone and mineral.

[30]  R. Boyce,et al.  Resorption is not essential for the stimulation of bone growth by hPTH‐(1‐34) in rats in vivo , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  E. Canalis,et al.  Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. , 1989, Endocrinology.

[32]  L. Bonewald,et al.  Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. , 1989, Biochemical and biophysical research communications.

[33]  E. Canalis,et al.  Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.

[34]  R M Neer,et al.  Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  R M Neer,et al.  Quantitative computed tomography for spinal density measurement. Factors affecting precision. , 1985, Investigative radiology.

[36]  Lee Goldman,et al.  Cecil Textbook of Medicine , 1985 .